Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
1500
Trial Sponsor
Clinical Trial Start Date
2003
0Study Completion Date
2006
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Interventional Trial Phase
Phase 20
Participating Facility
Official Name
A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study of Intravenous Daclizumab in Patients With Moderate-to-severe Ulcerative Colitis0
Last Updated
July 20, 2009
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Double0
Study summary
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38 clinical research centers in the US, Canada, and Belgium, and is open to male and female patients 12 years and older. Participants in the study will have a number of visits to a research center over a five-month period. All study related care and medication is provided to qualified participants at no cost: this includes all visits, examinations, and laboratory work.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
